You are here

selonsertib

AASLD 2020 – Nash updates from Novo and Inventiva in focus

EP Vantage

Wed, 11/4/20 - 10:09 am

Gilead Sciences

AASLD: Gilead wants to move the needle for fatty liver therapies

Fierce Biotech

Mon, 11/11/19 - 10:46 am

Gilead Sciences

clinical trials

Gilead's selonsertib fails PhIII in less sick NASH patients — to no one's surprise

Endpoints

Thu, 04/25/19 - 10:35 am

Gilead Sciences

clinical trials

Gilead shores up hope for NASH cocktail with a glimpse at positive proof-of-concept data

Endpoints

Thu, 04/11/19 - 12:33 pm

Gilead Sciences

It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial

Endpoints

Mon, 02/11/19 - 08:06 pm

Gilead Sciences

clinical trials

What’s up with all the buzz about Gilead’s PhIII NASH drug selonsertib?

Endpoints

Wed, 01/23/19 - 08:02 pm

clinical trials

Gilead Sciences

3 Biotech Stocks With Big News Coming in NASH

Motley Fool

Sat, 07/14/18 - 01:11 pm

Viking Therapeutics

Gilead Sciences

Intercept Pharma

Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis

CP Wire

Fri, 04/13/18 - 12:16 pm

Gilead Sciences

Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Fri, 04/13/18 - 12:10 pm

5 Drugs That Are Critical for Gilead Sciences' Future

Motley Fool

Thu, 02/22/18 - 09:18 am

Gilead Sciences

Good and bad news for Gilead

BioPharma Dive

Sat, 10/22/16 - 03:13 pm

Gilead Sciences

Gilead Fatty Liver Drug Advances to Phase 3

Investopedia

Fri, 10/21/16 - 10:05 am

Gilead Sciences

non-alcoholic fatty liver disease